• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Zimmer Biomet to Release New Data, Highlight Key Innovations at American Academy of Orthopaedic Surgeons Annual Meeting

    2/25/26 7:06:00 AM ET
    $ZBH
    Industrial Specialties
    Health Care
    Get the next $ZBH alert in real time by email

    Company's Chief Movement Officer, Arnold Schwarzenegger,

    Will Be Presidential Guest Speaker

    WARSAW, Ind., Feb. 25, 2026 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced it will unveil new clinical and operational data and showcase its newest innovations at the American Academy of Orthopaedic Surgeons (AAOS) 2026 Annual Meeting. The company's Chief Movement Officer Arnold Schwarzenegger will take center stage as the conference's Presidential Guest Speaker.

    Zimmer Biomet announced it will unveil new clinical and operational data and showcase its newest innovations at the American Academy of Orthopaedic Surgeons (AAOS) 2026 Annual Meeting, while the company's Chief Movement Officer Arnold Schwarzenegger will take center stage as the conference's Presidential Guest Speaker.

    On Thursday, March 5 at 10:30 a.m. Central Time, Schwarzenegger will be featured as the Presidential Guest Speaker, and will join Zimmer Biomet Chairman, President and CEO Ivan Tornos and AAOS President Ned Amendola, MD, FAAOS, FRCSC, DABOS, for a main-stage conversation about sustaining peak performance, teamwork and thriving under pressure.

    "Our presence at the AAOS Annual Meeting will highlight Zimmer Biomet's leadership in orthopedic implants coupled with the robotic and digital technologies that collect data before, during and after surgery to provide insights that help surgeons understand the potential impact of surgical decisions on patient outcomes," said Tornos. "In addition to the technologies we plan to showcase and new data being presented, we are very proud to feature our Chief Movement Officer, Arnold Schwarzenegger, as the Presidential Guest Speaker, and I look forward to joining him and Dr. Amendola for an engaging discussion."

    The company will highlight its wide variety of orthopedic innovations and solutions at booth 4239, including its most differentiated technologies that have built a reputation as the "Magnificent Seven," including:

    • Robotics and Navigation Technologies: From CT, to imageless to handheld robotics and AI-driven navigation technologies, Zimmer Biomet offers the industry's most comprehensive and adaptable suite of orthopedic robotics and navigation technologies designed to elevate surgical precision and transform patient outcomes.
      • ROSA® Knee with OptimiZe™: The newest version of the ROSA® Knee System to customize and enhance the surgeon's experience with personalized and intelligent surgical planning, new positioning, tracking and alignment features to improve accuracy1 and reduce user variability2 — and offers the industry's only automated kinematic alignment feature to resurface the knee with the goal of restoring its pre-arthritic position and native joint lines.
      • TMINI® Miniature Robotic System: A state-of-the-art miniature, handheld, wireless CT-based robotic system designed to enable accurate and precise3 implant placement.
      • Monogram Technologies TKA System: A CT-based, semi-autonomous, total knee arthroplasty (TKA) robotic technology that received U.S. Food and Drug Administration (FDA) 510(k) clearance in March 2025. A surgeon-guided, fully autonomous version of this technology is currently in clinical trials.
      • OrthoGrid Hip AI®: An AI-powered, fluoroscopy-based technology that provides hip surgeons with intuitive and instantaneous intra-operative tools to assist surgeons in achieving the desired surgical outcomes for component positioning.4



    • Oxford® Cementless Partial Knee: Celebrating 50 years of clinical heritage, the Oxford Partial Knee is the most widely used5 and clinically proven6,7 partial knee system in the world. It is also the only FDA-approved mobile cementless partial knee implant in the U.S. that has been shown to be efficient8,9 in the operating room and has been proven to have excellent survivorship10,11 worldwide.



    • Z1® Femoral Hip System: Offers an expansive size range and three distinct neck options designed to address a variety of patient anatomies and reconstructive needs.



    • Persona IQ® The Smart Knee®: The first and only smart knee implant that captures patient-specific gait and range of motion metrics directly from the knee during patient monitoring to provide post-operative recovery insights12,13 and trends, allowing care teams to monitor and personalize the TKA patient experience.10-14



    • Persona® OsseoTi® Keel Tibia: A cementless tibia for TKA with a 3D printed porous tray that provides stable initial and biological fixation and intra-operative versatility.15



    • HAMMR® Automated Hip Impaction System: Designed to address surgeon strain, fatigue and repetitive motion associated with the traditional mallet during hip replacement procedures, and provides a consistent, controlled and precise energy16 designed to minimize variability in both bone preparation and device implantation.



    • Persona® Revision Knee System: Expands the Persona Knee System to provide a portfolio of personalized knee care to replicate a patient's anatomy and offer an individualized fit in partial, primary and revision knee arthroplasties.

    New data being presented at the conference will highlight:

    • Safety and efficacy data for the Oxford® Cementless Partial Knee;
    • Efficiency improvement metrics when implementing new processes and workflows in ambulatory surgery centers (ASCs);
    • The relationship between early gait decline (collected with a smart implantable device) and periprosthetic joint infections in total knee arthroplasty (TKA);
    • The relationship between qualified step counts (collected with a smart implantable device) and venous thromboembolisms (blood clots) following primary TKA;
    • How the use of a smart implantable device and a digital care platform was associated with lower post-operative complications in knee replacement procedures;
    • The association between 90-day readmissions and immediate post-operative qualified step counts (collected with a smart implantable device) following primary TKA; and
    • New thresholds for post-operative gait metrics to help assess clinical significance in joint replacement patients.

    Zimmer Biomet exhibit will also feature the latest innovations in shoulder reconstruction, sports medicine, trauma, foot and ankle reconstruction from the company's recent Paragon 28 acquisition, along with solutions for infection prevention and the company's ZBX™ Ambulatory Surgery Center Solutions (ASCs) — a comprehensive approach to help surgeons locate, design, build and operate ASCs.

    About Zimmer Biomet

    Zimmer Biomet is a global medical technology leader with a comprehensive portfolio designed to maximize mobility and improve health. We seamlessly transform the patient experience through our innovative products and suite of integrated digital and robotic technologies that leverage data, data analytics and artificial intelligence.

    With 90+ years of trusted leadership and proven expertise, Zimmer Biomet is positioned to deliver the highest quality solutions to patients and providers. Our legacy continues to come to life today through our progressive culture of evolution and innovation. 

    For more information about our product portfolio, our operations in 25+ countries and sales in 100+ countries or about joining our team, visit www.zimmerbiomet.com or follow on LinkedIn at www.linkedin.com/company/zimmerbiomet or X at www.x.com/zimmerbiomet.

    Persona IQ: The objective kinematic data generated by the CSE with CHIRP System are not intended to support clinical decision-making and have not been shown to provide any clinical benefit.

    Cautionary Statement Regarding Forward-Looking Statements

    This news release contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements concerning Zimmer Biomet's expectations, plans, prospects, and product and service offerings, including new product launches and potential clinical successes. Such statements are based upon the current beliefs and expectations of management and are subject to significant risks, uncertainties and changes in circumstances that could cause actual outcomes and results to differ materially. For a list and description of some of such risks and uncertainties, see Zimmer Biomet's periodic reports filed with the U.S. Securities and Exchange Commission (SEC). These factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements that are included in Zimmer Biomet's filings with the SEC. Forward-looking statements speak only as of the date they are made, and Zimmer Biomet disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Readers of this news release are cautioned not to rely on these forward-looking statements, since there can be no assurance that these forward-looking statements will prove to be accurate. This cautionary statement is applicable to all forward-looking statements contained in this news release.

    Contacts:







    Media

    Investors

    Troy Kirkpatrick

    David DeMartino

    614-284-1926

    646-531-6115

    [email protected]

    [email protected]





    Kirsten Fallon

    Zach Weiner

    781-779-5561

    908-591-6955

    [email protected]

    [email protected]

    1 Data on File. DVaR-DS250106-01 ROSA Knee System v1.5 Validation Report.

    2 Data on File. FER-EMS230714-01 Formative Evaluation Report - July Lab 2023.

    3 Data on file at THINK Surgical. 2024. Data is based on TMINI System assisted placement of cut guide compared to planned placement.

    4 Cardenas JM, Gordon D, Waddell BS, Kitziger KJ, Peters PC Jr, Gladnick BP. Does Artificial Intelligence Outperform Humans Using Fluoroscopic-Assisted Computer Navigation for Total Hip Arthroplasty? Arthroplasty Today. 2024 May 27;27:101410. doi: 10.1016/j.artd.2024.101410. PMID: 38840694; PMCID: PMC11150909.

    5 Data on file at Zimmer Biomet. Based on Market Analysis and Registry Data, gathered September 2017.

    6 Price, A. and Svard, U. A Second Decade Lifetable Survival Analysis of the Oxford Unicompartmental Knee Arthroplasty. Clin Orthop Relat Res. 2011 Jan;469(1): 174-9.

    7 Pandit et al. The clinical outcome of minimally invasive phase 3 Oxford unicompartmental knee arthroplasty. Bone Joint J 2015;97-B:1493–1500.

    8 Pandit, H., et al. "Improved fixation in cementless unicompartmental knee replacement: five-year results of a randomized controlled trial." JBJS 95.15 (2013): 1365-1372.

    9 Stempin R, Kaczmarek W, Stempin K, Dutka J. Midterm Results of Cementless and Cemented Unicondylar Knee Arthroplasty with Mobile Meniscal Bearing: A Prospective Cohort Study. Open Orthop J. 2017 Oct 31;11:1173-1178. doi: 10.2174/1874325001711011173. PMID: 29290853; PMCID: PMC5721307.

    10 NJR- UK . The National Joint Registry 22nd Annual Report 2025 London, 2024 [Available from: https://reports.njrcentre.org.uk/Portals/0/PDFdownloads/NJR%2022nd%20Annual%20Report%202025_Knees.pdf.

    11 AOANJRR. Australian Orthopaedic Association National Joint Replacement Registry (AOANJRR). Hip, Knee & Shoulder Arthroplasty: 2023 Annual Report Adelaide, AOA2024 [updated 2024. Available from: https://aoanjrr.sahmri.com/documents/10180/1798900/AOANJRR+2024+Annual+Report.pdf/9d0bfe03-2282-8fc8-a424-b8d9abb82b1f?t=1727666185313.

    12 Cushner FD, Yergler J, ElashoffB, Aubin PM, VertaP, Scuderi GR. Staying Ahead of the Curve: The Case for Recovery Curves in Total Knee Arthroplasty. The Journal of Arthroplasty. 2024;doi:10.1016/j.arth.2024.07.039

    13 Cushner FD, Sculco PK, Long WJ. The Talking Knee Is a Reality: What Your Knee Can Tell You After Total Knee Arthroplasty. J OrthopaedicExperience and Innovation. 2022;2022

    14 Cushner FD, Schiller P, Gross J, Mueller JK, Hunter W. A Total Knee Arthroplasty Prosthesis Capable of Remote Patient Monitoring. OrthopaedicProceedings. 2021/06/01 2021;103-B(SUPP_9):18-18 doi:10.1302/1358-992X.2021.9.018

    15 Mueller J.K., et al. Persona OsseoTi Keel Tibia Provides Stable Initial Fixation 4027.2-GLBL-en. November 2022.

    16 Data on File at Zimmer Biomet. Zimmer HAMMR Verification Test Report. DOC0179677. Pages 47-49. January 19, 2024.

    (PRNewsfoto/Zimmer Biomet Holdings, Inc.)

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/zimmer-biomet-to-release-new-data-highlight-key-innovations-at-american-academy-of-orthopaedic-surgeons-annual-meeting-302696434.html

    SOURCE Zimmer Biomet Holdings, Inc.

    Get the next $ZBH alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ZBH

    DatePrice TargetRatingAnalyst
    2/20/2026Mkt Perform
    William Blair
    1/9/2026$93.00Neutral → Sell
    Goldman
    1/6/2026Outperform → Mkt Perform
    Raymond James
    1/5/2026$210.00In-line → Outperform
    Evercore ISI
    12/16/2025$100.00Outperform → Neutral
    Robert W. Baird
    11/6/2025$100.00Overweight → Neutral
    Analyst
    9/18/2025$130.00Buy
    Rothschild & Co Redburn
    7/15/2025$135.00Neutral → Buy
    Roth Capital
    More analyst ratings

    $ZBH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Officer Noor Jehanzeb

    4 - ZIMMER BIOMET HOLDINGS, INC. (0001136869) (Issuer)

    2/24/26 9:04:11 PM ET
    $ZBH
    Industrial Specialties
    Health Care

    Officer Phipps Chad F converted options into 2,246 shares and covered exercise/tax liability with 942 shares, increasing direct ownership by 2% to 62,137 units (SEC Form 4)

    4 - ZIMMER BIOMET HOLDINGS, INC. (0001136869) (Issuer)

    2/24/26 9:03:27 PM ET
    $ZBH
    Industrial Specialties
    Health Care

    SEC Form 4 filed by Grp Pres-Global Business Thornal Kevin R

    4 - ZIMMER BIOMET HOLDINGS, INC. (0001136869) (Issuer)

    2/24/26 9:02:45 PM ET
    $ZBH
    Industrial Specialties
    Health Care

    $ZBH
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Zimmer Biomet to Release New Data, Highlight Key Innovations at American Academy of Orthopaedic Surgeons Annual Meeting

    Company's Chief Movement Officer, Arnold Schwarzenegger,Will Be Presidential Guest SpeakerWARSAW, Ind., Feb. 25, 2026 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced it will unveil new clinical and operational data and showcase its newest innovations at the American Academy of Orthopaedic Surgeons (AAOS) 2026 Annual Meeting. The company's Chief Movement Officer Arnold Schwarzenegger will take center stage as the conference's Presidential Guest Speaker. On Thursday, March 5 at 10:30 a.m. Central Time, Schwarzen

    2/25/26 7:06:00 AM ET
    $ZBH
    Industrial Specialties
    Health Care

    Zimmer Biomet Announces Quarterly Dividend for First Quarter of 2026

    WARSAW, Ind., Feb. 23, 2026 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced that its Board of Directors has approved the payment of a quarterly cash dividend to stockholders for the first quarter of 2026. The cash dividend of $0.24 per share is payable on or about April 30, 2026 to stockholders of record as of the close of business on March 31, 2026. About Zimmer BiometZimmer Biomet is a global medical technology leader with a comprehensive portfolio designed to maximize mobility and improve health. We seamles

    2/23/26 7:00:00 AM ET
    $ZBH
    Industrial Specialties
    Health Care

    Zimmer Biomet Announces Fourth Quarter and Full-Year 2025 Financial Results

    Fourth quarter net sales of $2.244 billion increased 10.9% on a reported basis, 9.2% on a constant currency1 basis and 5.4% on an organic constant currency1 basisFourth quarter diluted earnings per share were $0.70, a decrease of 41.7%; adjusted1 diluted earnings per share were $2.42, an increase of 4.8%Full-year net sales of $8.232 billion increased 7.2% on a reported basis, 6.4% on a constant currency1 basis and 3.9% on an organic constant currency1 basisFull-year diluted earnings per share were $3.55, a decrease of 19.9%; adjusted1 diluted earnings per share were $8.20, an increase of 2.5%Company provides full-year 2026 financial guidanceWARSAW, Ind., Feb. 10, 2026 /PRNewswire/ -- Zimmer

    2/10/26 6:30:00 AM ET
    $ZBH
    Industrial Specialties
    Health Care

    $ZBH
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    William Blair initiated coverage on Zimmer Biomet

    William Blair initiated coverage of Zimmer Biomet with a rating of Mkt Perform

    2/20/26 8:25:46 AM ET
    $ZBH
    Industrial Specialties
    Health Care

    Zimmer Biomet downgraded by Goldman with a new price target

    Goldman downgraded Zimmer Biomet from Neutral to Sell and set a new price target of $93.00

    1/9/26 8:52:52 AM ET
    $ZBH
    Industrial Specialties
    Health Care

    Zimmer Biomet downgraded by Raymond James

    Raymond James downgraded Zimmer Biomet from Outperform to Mkt Perform

    1/6/26 8:47:57 AM ET
    $ZBH
    Industrial Specialties
    Health Care

    $ZBH
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Jafry Syed A. bought $223,641 worth of shares (2,135 units at $104.75), increasing direct ownership by 111% to 4,060 units (SEC Form 4)

    4 - ZIMMER BIOMET HOLDINGS, INC. (0001136869) (Issuer)

    11/13/23 4:02:02 PM ET
    $ZBH
    Industrial Specialties
    Health Care

    Begley Christopher B bought $117,114 worth of shares (1,000 units at $117.11), increasing direct ownership by 39% to 3,540 units (SEC Form 4)

    4 - ZIMMER BIOMET HOLDINGS, INC. (0001136869) (Issuer)

    9/29/23 4:05:41 PM ET
    $ZBH
    Industrial Specialties
    Health Care

    $ZBH
    SEC Filings

    View All

    SEC Form SCHEDULE 13G filed by Zimmer Biomet Holdings Inc.

    SCHEDULE 13G - ZIMMER BIOMET HOLDINGS, INC. (0001136869) (Subject)

    2/17/26 5:08:28 PM ET
    $ZBH
    Industrial Specialties
    Health Care

    Zimmer Biomet Holdings Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - ZIMMER BIOMET HOLDINGS, INC. (0001136869) (Filer)

    2/10/26 6:30:26 AM ET
    $ZBH
    Industrial Specialties
    Health Care

    SEC Form 8-K filed by Zimmer Biomet Holdings Inc.

    8-K - ZIMMER BIOMET HOLDINGS, INC. (0001136869) (Filer)

    1/12/26 9:00:34 AM ET
    $ZBH
    Industrial Specialties
    Health Care

    $ZBH
    Financials

    Live finance-specific insights

    View All

    Zimmer Biomet Announces Quarterly Dividend for First Quarter of 2026

    WARSAW, Ind., Feb. 23, 2026 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced that its Board of Directors has approved the payment of a quarterly cash dividend to stockholders for the first quarter of 2026. The cash dividend of $0.24 per share is payable on or about April 30, 2026 to stockholders of record as of the close of business on March 31, 2026. About Zimmer BiometZimmer Biomet is a global medical technology leader with a comprehensive portfolio designed to maximize mobility and improve health. We seamles

    2/23/26 7:00:00 AM ET
    $ZBH
    Industrial Specialties
    Health Care

    Zimmer Biomet Announces Fourth Quarter and Full-Year 2025 Financial Results

    Fourth quarter net sales of $2.244 billion increased 10.9% on a reported basis, 9.2% on a constant currency1 basis and 5.4% on an organic constant currency1 basisFourth quarter diluted earnings per share were $0.70, a decrease of 41.7%; adjusted1 diluted earnings per share were $2.42, an increase of 4.8%Full-year net sales of $8.232 billion increased 7.2% on a reported basis, 6.4% on a constant currency1 basis and 3.9% on an organic constant currency1 basisFull-year diluted earnings per share were $3.55, a decrease of 19.9%; adjusted1 diluted earnings per share were $8.20, an increase of 2.5%Company provides full-year 2026 financial guidanceWARSAW, Ind., Feb. 10, 2026 /PRNewswire/ -- Zimmer

    2/10/26 6:30:00 AM ET
    $ZBH
    Industrial Specialties
    Health Care

    Zimmer Biomet Announces Webcast and Conference Call of Fourth Quarter 2025 Financial Results

    WARSAW, Ind., Jan. 15, 2026 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced its fourth quarter earnings conference call will be webcast on Tuesday, February 10, 2026, at 8:30 a.m. ET. A news release detailing the quarterly results will be made available that day at 6:30 a.m. ET. A live audio webcast can be accessed via Zimmer Biomet's Investor Relations website at https://investor.zimmerbiomet.com. It will be available for replay following the conference call. Individuals in the U.S. and Canada who wish to d

    1/15/26 7:30:00 AM ET
    $ZBH
    Industrial Specialties
    Health Care

    $ZBH
    Leadership Updates

    Live Leadership Updates

    View All

    Zimmer Biomet Announces New Chief Medical Advisors to Help Improve Standard of Musculoskeletal Care

    Dr. Jonathan M. Vigdorchik Named Chief Medical Technology Advisor, Adult Reconstruction and Hip Implants Dr. Anand M. Murthi Appointed Chief Medical Advisor, Shoulder, Sports, Extremities, and Trauma (S.E.T.) WARSAW, Ind., Aug. 28, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced the appointments of Jonathan M. Vigdorchik, MD, as Chief Medical Technology Advisor focused on Adult Reconstruction and Hip Implants, and Anand M. Murthi, MD, FAAOS, as Chief Medical Advisor, Shoulder, Sports, Extremities, and Trauma (S.E.T.). As strategic advisors, Drs. Vigdorchik and Murthi will leverage their extensive clinical experience t

    8/28/25 7:30:00 AM ET
    $ZBH
    Industrial Specialties
    Health Care

    Zimmer Biomet Appoints Kevin Thornal as Group President, Global Businesses and the Americas

    WARSAW, Ind., May 27, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced the appointment of Kevin Thornal as Group President, Global Businesses and the Americas. Reporting to Chairman-Elect, President and CEO Ivan Tornos, Mr. Thornal will join the Company on July 1, 2025 to oversee the Americas commercial organization and lead business strategy and execution for its global Knees, Hips, S.E.T. and Data, Technology, and Enabling Solutions units. "Kevin is an incredible addition to our leadership team at an e

    5/27/25 7:30:00 AM ET
    $ZBH
    Industrial Specialties
    Health Care

    Zimmer Biomet Names Kristen Cardillo as Senior Vice President, Chief Communications Officer

    WARSAW, Ind., March 6, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced the appointment of Kristen Cardillo as Senior Vice President, Chief Communications Officer. Reporting to President and CEO Ivan Tornos, Ms. Cardillo will join the Company on March 10, 2025, to lead Zimmer Biomet's global communications strategy, enhancing engagement with key stakeholders and amplifying the Company's position as a leader in MedTech. "Kristen's expertise in shaping compelling corporate narratives and leading high-impac

    3/6/25 7:30:00 AM ET
    $ZBH
    Industrial Specialties
    Health Care

    $ZBH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Zimmer Biomet Holdings Inc.

    SC 13G - ZIMMER BIOMET HOLDINGS, INC. (0001136869) (Subject)

    11/14/24 1:22:34 PM ET
    $ZBH
    Industrial Specialties
    Health Care

    Amendment: SEC Form SC 13G/A filed by Zimmer Biomet Holdings Inc.

    SC 13G/A - ZIMMER BIOMET HOLDINGS, INC. (0001136869) (Subject)

    11/13/24 1:44:56 PM ET
    $ZBH
    Industrial Specialties
    Health Care

    SEC Form SC 13G filed by Zimmer Biomet Holdings Inc.

    SC 13G - ZIMMER BIOMET HOLDINGS, INC. (0001136869) (Subject)

    2/14/24 10:02:59 AM ET
    $ZBH
    Industrial Specialties
    Health Care